|
Name |
13-Ethenyl-19-hydroxy-5,7,9,11-tetramethyl-2-oxa-18-azahexacyclo[19.2.2.13,10.116,19.04,9.014,27]heptacosa-1(23),11,21,24-tetraene-15,17-dione
|
| Molecular Formula | C31H39NO4 | |
| IUPAC Name* |
13-ethenyl-19-hydroxy-5,7,9,11-tetramethyl-2-oxa-18-azahexacyclo[19.2.2.13,10.116,19.04,9.014,27]heptacosa-1(23),11,21,24-tetraene-15,17-dione
|
|
| SMILES |
CC1CC(C2C3C4C(C(C=C(C4C2(C1)C)C)C=C)C(=O)C5CC(CC6=CC=C(O3)C=C6)(NC5=O)O)C
|
|
| InChI |
InChI=1S/C31H39NO4/c1-6-20-12-18(4)25-24-23(20)27(33)22-15-31(35,32-29(22)34)14-19-7-9-21(10-8-19)36-28(24)26-17(3)11-16(2)13-30(25,26)5/h6-10,12,16-17,20,22-26,28,35H,1,11,13-15H2,2-5H3,(H,32,34)
|
|
| InChIKey |
OCUONUXNKYDHKY-UHFFFAOYSA-N
|
|
| Synonyms |
Pyrrocidine B; BS-1234
|
|
| CAS | NA | |
| PubChem CID | 129008868 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 489.6 | ALogp: | 5.5 |
| HBD: | 2 | HBA: | 4 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 75.6 | Aromatic Rings: | 7 |
| Heavy Atoms: | 36 | QED Weighted: | 0.423 |
| Caco-2 Permeability: | -4.717 | MDCK Permeability: | 0.00011547 |
| Pgp-inhibitor: | 0.537 | Pgp-substrate: | 0.007 |
| Human Intestinal Absorption (HIA): | 0.043 | 20% Bioavailability (F20%): | 0.116 |
| 30% Bioavailability (F30%): | 0.008 |
| Blood-Brain-Barrier Penetration (BBB): | 0.362 | Plasma Protein Binding (PPB): | 98.27% |
| Volume Distribution (VD): | 1.575 | Fu: | 1.66% |
| CYP1A2-inhibitor: | 0.034 | CYP1A2-substrate: | 0.9 |
| CYP2C19-inhibitor: | 0.73 | CYP2C19-substrate: | 0.913 |
| CYP2C9-inhibitor: | 0.472 | CYP2C9-substrate: | 0.162 |
| CYP2D6-inhibitor: | 0.039 | CYP2D6-substrate: | 0.458 |
| CYP3A4-inhibitor: | 0.907 | CYP3A4-substrate: | 0.838 |
| Clearance (CL): | 12.15 | Half-life (T1/2): | 0.016 |
| hERG Blockers: | 0.268 | Human Hepatotoxicity (H-HT): | 0.567 |
| Drug-inuced Liver Injury (DILI): | 0.901 | AMES Toxicity: | 0.02 |
| Rat Oral Acute Toxicity: | 0.998 | Maximum Recommended Daily Dose: | 0.946 |
| Skin Sensitization: | 0.024 | Carcinogencity: | 0.035 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
| Respiratory Toxicity: | 0.942 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC005320 | ![]() |
0.845 | D0V4WD | ![]() |
0.227 | ||
| ENC004853 | ![]() |
0.772 | D0W2EK | ![]() |
0.220 | ||
| ENC003137 | ![]() |
0.739 | D0VA0I | ![]() |
0.216 | ||
| ENC004852 | ![]() |
0.714 | D0I5DS | ![]() |
0.210 | ||
| ENC005770 | ![]() |
0.647 | D04SFH | ![]() |
0.209 | ||
| ENC003851 | ![]() |
0.602 | D0F1EX | ![]() |
0.207 | ||
| ENC003989 | ![]() |
0.589 | D0E9KA | ![]() |
0.205 | ||
| ENC003503 | ![]() |
0.578 | D09WYX | ![]() |
0.205 | ||
| ENC005769 | ![]() |
0.485 | D05VQI | ![]() |
0.202 | ||
| ENC005768 | ![]() |
0.482 | D08PIQ | ![]() |
0.201 | ||